Researchmoz presents this most up-to-date research on"Latest Research
On Pharmaceutical Market Israel,Belarus,Finland and Moldova Report At
Researchmoz.us". The report focuses primarily on quantitative market
metrics in order to characterize the growth and evolution of the Remote
Patient Monitoring Market.
The Pharmaceutical Market: Israel http://www.researchmoz.us/the-pharmaceutical-market-israel-report.html
Although
Israel claims its very efficient healthcare system means it
does not need to spend as much of its GDP on provision (some 7.6% was
spent on this purpose in 2011), in reality the government's fiscal
austerity and sick funds traditionally keep the most expensive
innovative drugs and treatments unavailable. Additionally, as healthcare
providers are prohibited from taking on debt, the shortage means that
cheaper generics and low staff salaries have to be used to control
overall costs, which often comes at the expense of services provided to
patients. However, the recent ruling means that the state must increase
payments to healthcare providers in order to account for rising costs,
which provide some upside risks to healthcare forecasts. The competitive
landscape section provides comparative company analyses
and rankings by US$ sales and % share of total sales - for the total
pharmaceutical sector, as well as the OTC, generics, and distribution
sub-sectors.
The Pharmaceutical Market: Belarus http://www.researchmoz.us/the-pharmaceutical-market-belarus-report.html
We remain largely pessimistic about
the Belarus' pharmaceutical market development in the short term at
least. While the government remains committed to boosting domestic
pharmaceutical output over the coming years, with authorities in
manufacturing joint venture (JV) discussions with a number of countries,
the devalued rouble, high inflation and weak household consumption will
continue to constrain both volume and value of medicines consumed in
the country. We also note increased political and also economic risks,
as the country aligns itself away from the European Union (EU).The Pharmaceutical risk/reward rating
(RRR) score for Belarus worsened in Q113, largely on account of high
levels of inflation and the corresponding weak growth in US dollar
terms. The country remains viewed as one of the least attractive
pharmaceutical markets in Central and Eastern Europe (CEE), ranking 18th
out of 20 countries surveyed regionally. Risks also remain elevated,
both on the political and economic fronts.
The competitive landscape section
provides comparative company analyses and rankings by US$ sales and %
share of total sales - for the total pharmaceutical sector, as well as
the OTC, generics, and distribution sub-sectors.
The Pharmaceutical Market: Finland http://www.researchmoz.us/the-pharmaceutical-market-finland-report.html
The macroenvironment for the Finnish
pharmaceutical industry is improving.Politically, the new six-party
coalition is larger and represents a broader spectrum of opinion than is
usual, which could make it unstable. However, the Economist
Intelligence Unit (EIU) believes that it will last out its four-year
term. Economically, recovery from the downturn is stalling due to the
euro area debt crisis. Legally, Finland remains on the USTR’s Watch List
in 2011 due to concerns over patent protection. Demographically,
Finland has one of the largest proportions of population over the age of
65 in Western Europe. Latest projections expect that the population
aged 65 and over will constitute more than one-fifth of the total
population by 2017. The ageing population means that healthcare is
increasingly focused on preventative care.
The Finnish government has introduced
several cost-containment measures in recent years in an effort to curb
rising healthcare costs. One of the latest affecting the pharmaceutical
market in Finland is a reference pricing system. It is hoped that the
new system will reduce the use of expensive pharmaceutical products,
thus lowering the costs for patients and reducing the pressure to raise
health insurance payments. Generic substitution in Finland has been
extended to include products with an analogy process patent. As a
result, generic substitution will be more effective in terms of saving
money, but Finnish manufacturers of patented original products now enter
generic price competition several years before product patents expire
in other European countries.
The Pharmaceutical Market: Moldova http://www.researchmoz.us/the-pharmaceutical-market-moldova-report.html
Given the high level of reliance on out-of-pocket payments, the growth
of the Moldova's pharmaceutical market is expected to be shaped by the
prevailing economic conditions, both at home and abroad, on account of
the importance of remittances to the country's GDP. For 2012, we expect
the market's value to increase at a local currency rate of 6.7%,
although this will translate into negative US dollar growth, on the back
of a weak leu .
Moldova's Pharmaceutical Risk/Reward
Rating (RRR) score, which assesses the country's attractiveness to
multinational drugmakers, remains unchanged at 41.8 for Q1 13. The score
places the country second from the bottom in the regional matrix
assessing 20 key markets in Central and Eastern Europe. Moldova's risks
and rewards are relatively evenly balanced, although both remain
considerably lower than the regional averages.
For More Information Kindly Contact:
Email: sales@researchmoz.us
Web Site: http://www.researchmoz.us/
Blog: http://deepmarketresearchreports.blogspot.com
word press : http://marketresearchtopix.wordpress.com
Email: sales@researchmoz.us
Web Site: http://www.researchmoz.us/
Blog: http://deepmarketresearchreports.blogspot.com
word press : http://marketresearchtopix.wordpress.com
